Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.58 |
| ▸ | TFEB | P19484 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.48 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372144 | 1.00 | NFE2L2 (0.58) | NFE2L2TRPA1TFEBKDM4EALDH1A1 | |
| SCHEMBL257125 | 1.00 | NFE2L2 (0.58) | NFE2L2TRPA1TFEBKDM4EALDH1A1 | |
| SCHEMBL30678623 | 0.88 | NFE2L2 (0.62) | NFE2L2TRPA1TFEBKDM4EALDH1A1 | |
| SCHEMBL29805387 | 0.88 | NFE2L2 (0.62) | NFE2L2TRPA1TFEBKDM4EALDH1A1 | |
| SCHEMBL10781099 | 0.86 | NFE2L2 (0.41) | NFE2L2TRPA1TFEBKDM4EALDH1A1 | |
| SCHEMBL11432051 | 0.85 | NFE2L2 (0.55) | NFE2L2TRPA1TFEBKDM4EALDH1A1 | |
| SCHEMBL11432044 | 0.85 | NFE2L2 (0.55) | NFE2L2TRPA1TFEBKDM4EALDH1A1 | |
| SCHEMBL13570118 | 0.83 | NFE2L2 (0.60) | NFE2L2KDM4ECYP1A1CYP1A2CYP1B1 | |
| SCHEMBL1603719 | 0.83 | NFE2L2 (0.79) | NFE2L2TRPA1TFEBKDM4EALDH1A1 | |
| SCHEMBL4019329 | 0.83 | NFE2L2 (0.79) | NFE2L2TRPA1TFEBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286195-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | AbbVie Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016168638-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| EP-1658298-B1 | PHOSPHORUS-CONTAINING IMIDAZOLINES AND METAL COMPLEXES THEREOF | SOLVIAS AG (CH) | 2008-03-26 | — | — | EP | disclosed |
| US-20070010493-A1 | Phospinite-imidazolines and metal complexes thereof | SOLVIAS AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1658298-A2 | NOVEL ORGANIC COMPOUNDS AND METAL COMPLEXES | Solvias AG (CH) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005021562-A2 | PHOSPINITE-IMIDAZOLINES AND METAL COMPLEXES THEREOF | SOLVIAS AG (CH) | 2005-03-10 | — | — | WO | disclosed |
| EP-1478403-A1 | RESPONSIVE MICROGEL AND METHODS RELATED THERETO | SUPRATEK PHARMA, INC. (CA) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003063909-A1 | RESPONSIVE MICROGEL AND METHODS RELATED THERETO | SUPRATEK PHARMA INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| US-4962253-A | Vinylation of aromatics catalyzed by cyclopentadienyl, indenyl, or fluorenyl rhodium complexes, and novel indenyl and fluorenyl rhodium complexes | THE DOW CHEMICAL COMPANY (US) | 1990-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010493-A1 | Phospinite-imidazolines and metal complexes thereof | H1-0, H1-2, H1-3 | NFE2L2 650/4885TRPA1 508/4885TFEB 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.